Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...
Pancreatic cancer reprograms nerve cells to fuel its growth, but blocking these connections can shrink tumors and boost ...
Scientists at Oregon Health and Science University (OHSU) have developed a new blood test for pancreatic cancer, one of the ...
The study developed a noninvasive detection method based on serum protease activity, leveraging the increased protease activity in the peripheral blood of patients with PDAC. Researchers screened a ...
Pancreatic cancer is the 10th deadliest form of cancer in the United States, according to the National Cancer Institute.
In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...
A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease ...
The mRNA vaccine works by targeting genetic mutations found in pancreatic cancer, alerting the immune system to recognize and ...
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...
The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...
Scientists have developed a new mRNA vaccine to treat pancreatic cancer that may extend patients' lifespans by 8 to 10 years.
A personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery, according to a preliminary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results